Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193608 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01193608 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 88 participants.
The verdict
NCT01193608, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.
Interventions
- DRUG AAB-003 (PF-05236812)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193608
The ClinicalTrials.gov registry entry for NCT01193608 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AAB-003 (PF-05236812) is the first listed.
NCT01193608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193608 about?
NCT01193608 is a clinical study titled "Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease". This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.
What is the current status of trial NCT01193608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2010-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01193608?
The interventions under investigation include: AAB-003 (PF-05236812) (DRUG).
Who is sponsoring clinical trial NCT01193608?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.